$WNLV
Winvest Group Ltd

2021 Q3 Form 10-Q Financial Statement

#000182912621013743 Filed on November 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $52.31K $32.30K $1.300K
YoY Change 3923.85%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $52.31K $38.18K $1.300K
YoY Change 3923.85%
Operating Profit -$52.31K -$38.18K
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$52.31K -$32.30K -$1.300K
YoY Change 3923.85%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$52.31K -$38.18K -$1.300K
YoY Change 3923.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$25.16K -$62.07 -$2.50
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets $0.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.300K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $93.19K $32.30K $27.52K
YoY Change 238.63%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $100.5K $32.30K $27.52K
YoY Change 265.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $100.5K $32.30K $27.52K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $100.5K $32.30K $27.52K
YoY Change 265.12%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$100.5K -$86.62K -$27.52K
YoY Change
Total Liabilities & Shareholders Equity $0.00
YoY Change

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q3
OPERATING ACTIVITIES
Net Income -$52.31K -$38.18K -$1.300K
YoY Change 3923.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$45.35K -$2.502M -$1.300K
YoY Change 3388.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.35K 2.502M 1.300K
YoY Change 3388.46%
NET CHANGE
Cash From Operating Activities -45.35K -2.502M -1.300K
Cash From Investing Activities
Cash From Financing Activities 45.35K 2.502M 1.300K
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$45.35K -$2.502M -$1.300K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
USD
CY2021Q3 us-gaap Revenues
Revenues
USD
CY2021Q2 us-gaap Assets
Assets
USD
CY2021Q2 us-gaap Assets
Assets
USD
CY2020Q3 us-gaap Revenues
Revenues
USD
CY2021Q2 us-gaap Revenues
Revenues
USD
CY2020Q2 us-gaap Revenues
Revenues
USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2020Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
USD
CY2020Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD

Files In Submission

Name View Source Status
0001829126-21-013743-index-headers.html Edgar Link pending
0001829126-21-013743-index.html Edgar Link pending
0001829126-21-013743.txt Edgar Link pending
0001829126-21-013743-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zyroxmining_10q.htm Edgar Link pending
zyroxmining_10q_htm.xml Edgar Link completed
zyroxmining_ex31-1.htm Edgar Link pending
zyroxmining_ex31-2.htm Edgar Link pending
zyroxmining_ex32-1.htm Edgar Link pending
zyroxmining_ex32-2.htm Edgar Link pending
zyrx-20210930.xsd Edgar Link pending
zyrx-20210930_cal.xml Edgar Link unprocessable
zyrx-20210930_def.xml Edgar Link unprocessable
zyrx-20210930_lab.xml Edgar Link unprocessable
zyrx-20210930_pre.xml Edgar Link unprocessable